文献速递心外重症与机械循环支持

美国经皮左心室辅助装置作为心脏移植桥接的使用现状:UNOS数据库深度分析

Utilization of the percutaneous left ventricular support as bridge to heart transplantation across the United States: In-depth UNOS database analysis.
PubMed 文献 · J Heart Lung Transplant · 2023-06-10

该回顾性纵向研究基于UNOS登记数据,纳入2018年10月至2022年4月以状态2列名且需IABP或Impella支持的成人心脏移植候选者4178例(Impella 650例,IABP 3528例)。结果显示Impella组医学 acuity 更高且以状态2成功移植率低于IABP组(92.1% vs 88.9%,p<0.001)。作者认为Impella替代IABP并未改善等待名单结局,需客观证据指导临时机械循环支持使用并改革UNOS分配系统。

要点

  • Impella组以状态2成功移植率低于IABP组(92.1% vs 88.9%,p<0.001)。
  • 等待名单死亡率从2019年最低16例/千状态2列名患者升至2022年最高36例/千状态2列名患者。
  • IABP:Impella使用比在各地区间差异大(1.77至21.31),南部和西部各州Impella使用率高。

核心结论

  • Impella替代IABP并未改善等待名单结局,临床实践模式而非单纯器械选择决定成功桥接至心脏移植。

研究设计与样本

  • 回顾性纵向研究,基于UNOS登记数据集,纳入2018年10月至2022年4月以状态2列名且需IABP或Impella支持的成人心脏移植候选者4178例(Impella 650例,IABP 3528例)。

主要发现

  • 研究期间共32806例心脏移植,4178例符合纳入标准(Impella 650例,IABP 3528例)。
  • 等待名单死亡率从2019年最低16例/千状态2列名患者升至2022年最高36例/千状态2列名患者。
  • Impella年使用率从2019年8%升至2021年19%。
  • 与IABP相比,Impella患者医学 acuity 更高且以状态2成功移植率更低(92.1% vs 88.9%,p<0.001)。
  • IABP:Impella使用比在各地区间差异大(1.77至21.31),南部和西部各州Impella使用率高,但该差异不能由医学 acuity、地区移植量或等待名单时间解释,且与等待名单死亡率不相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intra-aortic balloon pump (IABP) and Impella device utilization as a bridge to heart transplantation (HTx) have risen exponentially. We aimed to explore the influence of device selection on HTx outcomes, considering regional practice variation. METHODS: A retrospective longitudinal study was performed on a United Network for Organ Sharing (UNOS) registry dataset. We included adult patients listed for HTx between October 2018 and April 2022 as status 2, as justified by requiring IABP or Impella support. The primary end-point was successful bridging to HTx as status 2. RESULTS: Of 32,806 HTx during the study period, 4178 met inclusion criteria (Impella n = 650, IABP n = 3528). Waitlist mortality increased from a nadir of 16 (in 2019) to a peak of 36 (in 2022) per thousand status 2 listed patients. Impella annual use increased from 8% in 2019 to 19% in 2021. Compared to IABP, Impella patients demonstrated higher medical acuity and lower success rate of transplantation as status 2 (92.1% vs 88.9%, p < 0.001). The IABP:Impella utilization ratio varied widely between regions, ranging from 1.77 to 21.31, with high Impella use in Southern and Western states. However, this difference was not justified by medical acuity, regional transplant volume, or waitlist time and did not correlate with waitlist mortality. CONCLUSIONS: The shift in utilizing Impella as opposed to IABP did not improve waitlist outcomes. Our results suggest that clinical practice patterns beyond mere device selection determine successful bridging to HTx. There is a critical need for objective evidence to guide tMCS utilization and a paradigm shift in the UNOS allocation system to achieve equitable HTx practice across the United States.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Al-Ani MA, Bai C, Bledsoe M, et al. Utilization of the percutaneous left ventricular support as bridge to heart transplantation across the United States: In-depth UNOS database analysis. J Heart Lung Transplant. 2023. PMID: 37307906. doi:10.1016/j.healun.2023.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。